Pulse Biosciences

3957 Point Eden Way
Hayward
CA
94545
United States

Tel: 833-257-3393

Website: https://www.pulsebiosciences.com/

About Pulse Biosciences

Pulse Biosciences, Inc. is a bioelectric medicine company pursuing commercial introduction of our proprietary CellFX® System initially to the dermatology market. The CellFX System is powered by Nano-Pulse Stimulation™ (NPS™) technology, which delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular skin tissue. The unique cell-specific effects have the potential to significantly benefit patients across multiple medical applications. Designed as a multi-application platform, the initial commercial use of the CellFX System (upon regulatory approval) is expected to address a broad range of dermatologic conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes.

Stock Symbol: PLSE

120 articles with Pulse Biosciences

Pulse Biosciences to Host Quarterly Investor Conference Call on November 7, 2017

10/25/2017

Pulse Biosciences, Inc. announced it will host its quarterly investor conference call on Tuesday, November 7, 2017 at 1:30 p.m. PST / 4:30 p.m. EST.
Bay Area's Pulse Biosciences Withdraws 510(K) App for Its PulseTx System

9/11/2017
Pulse Biosciences Quarterly Investor And Analyst Conference Call

7/28/2017
Pulse Biosciences To Host Quarterly Investor Conference Call On July 27, 2017

7/12/2017
Pulse Biosciences Announces Treatment Of First Patient In Study To Evaluate The Safety And Efficacy Of Novel Nano-Pulse Stimulation Technology For Seborrheic Keratosis Lesions

6/6/2017
Pulse Biosciences Quarterly Investor Conference Call

5/4/2017
Pulse Biosciences To Host Quarterly Investor Conference Call On May 4, 2017

4/18/2017
Pulse Biosciences Quartery Investor Conference Call

3/15/2017
Pulse Biosciences Submits 510(k) Application To FDA For PulseTx System

3/14/2017
Pulse Biosciences To Host Investor Conference Call On March 14, 2017

3/2/2017
Ex-Pharmacyclics CEO, COO Take 17% Stake in Bay Area's Pulse Biosciences

2/13/2017
Pulse Biosciences Announces Healthcare Executives And Entrepreneurs Robert Duggan And Dr. Maky Zanganeh Have Acquired A Combined Interest Of 17.1% Of The Company

2/10/2017
Pulse Biosciences Announces First Clinical Use Of The Proprietary Pulsetx Platform In A Pilot Study In Dermatology

11/14/2016
Pulse Biosciences Announces New Data That Reinforce Potential Immuno-Oncology Benefits Of Nano-Pulse Stimulation Technology

11/11/2016
Pulse Biosciences To Host Third Quarter Investor Conference Call On November 14, 2016

11/3/2016
Pulse Biosciences Provides Overview Of Corporate Strategy And Updates On Clinical Development For Novel Pulsetx Platform

9/8/2016
Pulse Biosciences Appoints Holly Hartman As Vice President Of Business Development And Corporate Strategy

8/31/2016
Pulse Biosciences Appoints Edward Ebbers As Vice President And General Manager Of Dermatology Products

8/25/2016
Pulse Biosciences To Host September Investor Conference Call To Highlight Corporate Progress, Strategic Focus And Future Milestones

8/11/2016
Pulse Biosciences Registers for $20 Million IPO

12/29/2015